Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aas, T., Børressen, A-L & Geisler, S. et al (1996). Spesific p53 mutations are associated with de novo resistance to doxorubicine in breast cancer patients. Nat Med 2: 811–814.
Colleoni, M., Pricer, K. & Catiglione-Gertsch, M. et al (1998). Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 34: 1693–1700.
Hawkins, D., Demers, G. & Galloway, D. (1996). Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892–898.
Poikonen, P., Saarto, T., Lundin, J., Joensuu, H. & Blomquist, C. (1999). Leucocyte nadir as a marker for chemotherapy efficacy in node positive breast cancer treated with adjuvant CMF. Br J Cancer (in press)
Saarto, T., Blomquist, C., Rissanen, P., Auvinen, A. & Elomaa, I. (1997). Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75: 301–305.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kvinnsland, S. The leucocyte nadir, a predictor of chemotherapy efficacy?. Br J Cancer 80, 1681 (1999). https://doi.org/10.1038/sj.bjc.6690583
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690583